TGFB1 and hematoma: There are several potential explanations for the divergent findings: in the previous study, TGF-β1 was measured in plasma whereas we measured our cytokines in the serum; we did not compare cytokine levels to those of non-neurologic controls (whereas the previous study did); our patients were “sicker” overall—with higher hematoma volumes and ICH scores; we sampled additional timepoints through day 10.